Annovis Bio $6 Million Registered Direct Offering FAQ
Summary
Annovis Bio Inc. (NYSE: ANVS) has successfully closed a $6 million registered direct offering of 4 million shares at $1.50 per share. The net proceeds will be used for working capital and general corporate purposes to support the company's development of neurodegenerative disease therapies.
What is the main announcement in this content?
Annovis Bio Inc. has closed a registered direct offering of 4 million shares of common stock at $1.50 per share, generating approximately $6 million in gross proceeds before fees and expenses.
How much money did Annovis Bio raise in this offering?
The company raised approximately $6 million in gross proceeds before deducting fees and expenses associated with the offering.
What will the proceeds from this offering be used for?
The net proceeds are intended for working capital and general corporate purposes to support the company’s operations and development activities.
Who served as the placement agent for this offering?
H.C. Wainwright & Co. served as the exclusive placement agent for the registered direct offering.
What type of company is Annovis Bio?
Annovis Bio is a late-stage clinical drug platform company that develops therapies for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
Where is Annovis Bio headquartered?
The company is headquartered in Malvern, Pennsylvania.
How can investors get more information about Annovis Bio?
Investors can visit the company’s website at www.annovisbio.com, follow them on LinkedIn, YouTube, and X, or access the latest news and updates in the company’s newsroom at https://ibn.fm/ANVS.
What is the significance of this funding for Annovis Bio?
This funding provides essential capital for working capital and general corporate purposes, supporting the company’s continued development of innovative therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s.
Where can I view the full press release about this offering?
The full press release can be viewed at https://ibn.fm/p55Nb.
What is InvestorWire’s role in this content?
InvestorWire is a specialized communications platform that provides wire-grade press release syndication and distribution services for companies like Annovis Bio, helping them reach target markets and the investment community.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 255047